BioMarin Pharmaceutical, Inc. (BMRN)
56.70
-1.63
(-2.79%)
USD |
NASDAQ |
Nov 12, 16:00
56.70
0.00 (0.00%)
After-Hours: 20:00
BioMarin Pharmaceutical Price to Book Value : 1.755 for Nov. 12, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 1.755 |
| November 11, 2026 | 1.806 |
| November 10, 2026 | 1.769 |
| November 09, 2026 | 1.770 |
| November 06, 2026 | 1.735 |
| November 05, 2026 | 1.737 |
| November 04, 2026 | 1.769 |
| November 03, 2026 | 1.723 |
| November 02, 2026 | 1.778 |
| October 30, 2026 | 1.811 |
| October 29, 2026 | 1.780 |
| October 28, 2026 | 1.734 |
| October 27, 2026 | 1.714 |
| October 26, 2026 | 1.726 |
| October 23, 2026 | 1.732 |
| October 22, 2026 | 1.753 |
| October 21, 2026 | 1.709 |
| October 20, 2026 | 1.747 |
| October 19, 2026 | 1.692 |
| October 16, 2026 | 1.693 |
| October 15, 2026 | 1.735 |
| October 14, 2026 | 1.707 |
| October 13, 2026 | 1.684 |
| October 12, 2026 | 1.715 |
| October 09, 2026 | 1.696 |
| Date | Value |
|---|---|
| October 08, 2026 | 1.699 |
| October 07, 2026 | 1.709 |
| October 06, 2026 | 1.740 |
| October 05, 2026 | 1.781 |
| October 02, 2026 | 1.770 |
| October 01, 2026 | 1.809 |
| September 30, 2026 | 1.858 |
| September 29, 2026 | 1.833 |
| September 28, 2026 | 1.820 |
| September 25, 2026 | 1.845 |
| September 24, 2026 | 1.878 |
| September 23, 2026 | 1.904 |
| September 22, 2026 | 1.94 |
| September 21, 2026 | 1.961 |
| September 18, 2026 | 1.958 |
| September 17, 2026 | 1.992 |
| September 16, 2026 | 1.982 |
| September 15, 2026 | 1.973 |
| September 14, 2026 | 2.033 |
| September 11, 2026 | 2.011 |
| September 10, 2026 | 2.006 |
| September 09, 2026 | 1.972 |
| September 08, 2026 | 1.979 |
| September 04, 2026 | 2.037 |
| September 03, 2026 | 2.034 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Exelixis, Inc. | 9.318 |
| Ascendis Pharma A/S | 10.68 |
| Alnylam Pharmaceuticals, Inc. | 5.819 |
| Anika Therapeutics, Inc. | 1.344 |
| Cytokinetics, Inc. | -- |
Price to Book Value Related Metrics
| PS Ratio | 2.985 |
| Price to Free Cash Flow | 19.85 |
| Price | 56.70 |
| Earnings Yield | -0.18% |
| Market Cap | 10.98B |
| Operating PE Ratio | 15.55 |
| Normalized PE Ratio | 29.71 |